On April 29, 2026 Syncromune, Inc., a clinical-stage biopharmaceutical company advancing SYNC-T, an investigational platform combination immunotherapy for metastatic solid tumor cancers, reported an oral presentation at the 2026 European Conference on Interventional Oncology (ECIO) in Basel, Switzerland. The oral presentation reflects continued clinical and scientific interest in the SYNC-T platform as development progresses.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation, titled "Abscopal effects of an Image-Guided Percutaneous Combination Device/Drug Immunotherapy Approach to Metastatic Prostate Cancer," was delivered by Stephen Kee, M.D., EVP, Clinical Medical & Business Operations, EMEA, at Syncromune. Dr. Kee described the minimally invasive outpatient SYNC-T combination drug/device immunotherapy procedure, noting that a single needle/infusion sheath device is placed percutaneously under image guidance into the center of a target tumor, either primary or metastatic. A cycle of partial cryolysis is then performed to disrupt tumor cell membranes and release tumor-derived antigens into the tumor microenvironment (TME), facilitating immune recognition. Immediately following lysis, a fixed dose of the multi-target drug SV-102 is infused through the same device into the zone of lysis where it co-locates with tumor antigens in the TME.
The infusion volume is designed to promote the flow of tumor antigens and SV-102 into regional lymphatics, where they synchronize location with immune cells. This synchronization approach is intended to create conditions for T cell activation and a systemic anti-tumor response, also known as an abscopal effect. SYNC-T’s intratumoral delivery enables effective high dose local drug concentrations while limiting systemic exposure, which may reduce immune-related toxicity.
"ECIO brings together experts who understand the clinical implications of innovative cancer therapies like SYNC-T," said Stephen Kee, M.D., presenter of the ECIO oral presentation and EVP, Clinical Medical & Business Operations, EMEA at Syncromune. "Today’s presentation highlights the distinct procedural logic of SYNC-T: combining partial cryolysis and intratumoral infusion through a single device using an image-guided percutaneous method. This novel approach has the potential to drive systemic anti-tumor responses, including regression of metastatic lesions, while maintaining a favorable tolerability profile."
Charles Link, M.D., Executive Chairman and Chief Innovation Officer of Syncromune added: "SYNC-T is designed to integrate cryolysis with a precisely coordinated immunomodulatory biologic, through a streamlined minimally invasive procedure intended to generate systemic anti-tumor effects. The Phase 1 clinical findings reviewed today continue to support the potential of the SYNC-T platform as we advance our ongoing Phase 2 LEGION-100 trial in patients with metastatic castration-resistant prostate cancer and support the broader potential of the platform across metastatic solid tumors."
The presentation also reviewed previously reported preliminary Phase 1 findings supporting the clinical rationale for the approach. In a single-arm study of 15 patients with metastatic prostate cancer, SYNC-T Therapy SV-102 demonstrated an overall response rate of 87%, including complete responses in 53% of patients. Among the 13 patients with bone metastases at baseline, all bone metastases resolved in seven patients (54%), as confirmed by imaging. Median time to response was 2.9 months, median duration of response was 12.1 months, and median overall survival had not been reached at 17.2 months of follow-up.
Previously reported safety findings were also reviewed. A total of 41 treatment-emergent adverse events were observed in 13 patients, with 95% graded 1 or 2. The most common events were hematuria and fever. Two Grade 2 immune-related adverse events and two Grade 3 treatment-emergent adverse events were reported, with no Grade 4 or 5 events observed.
Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com to learn more.
(Press release, Syncromune, APR 29, 2026, https://www.globenewswire.com/news-release/2026/04/29/3283931/0/en/syncromune-inc-presents-innovative-sync-t-combination-immunotherapy-approach-at-major-european-interventional-oncology-conference.html [SID1234664925])